VSTM vs ZBIO Stock Comparison
VSTM currently leads ZBIO in this stock comparison, with AIQ scores of 60 vs 47. The clearest difference is value.
What is the main difference between VSTM and ZBIO?
VSTM leads the current stock comparison as Verastem, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Verastem, Inc. vs Zenas BioPharma, Inc.
VSTM leads
VSTM leads by 13 AIQ points, primarily on Value and Quality.
Competitive: 4 of 6 evidence groups support VSTM, and its current signal state is conflicted.
Verastem, Inc.
Zenas BioPharma, Inc.
The Algovestiq AIQ Score currently favors VSTM over ZBIO, 60 versus 47 as of Nov 15, 2026. VSTM's advantage is driven primarily by stronger value and quality. VSTM also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor VSTM today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions.
Compare Verastem, Inc. and Zenas BioPharma, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare VSTM and ZBIO against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value53 vs 33VSTM +20
- Quality42 vs 25VSTM +17
- Momentum89 vs 78VSTM +11
- Risk Resilience36 vs 39Even
4 of 6 evidence groups favor VSTM. VSTM’s edge is concentrated in value and quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Momentum -2, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 4 active signals are unchanged.
Largest factor move: Momentum +2
New signals
- Beta Spike Warning — bearish, risk_regime, long horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
- RSI Midline Reclaim — bullish, momentum, short horizon
VSTM's lead narrowed by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — VSTM and ZBIO both carry a full feed there.
The central trade-off
VSTM (Verastem, Inc.): the stronger current systematic profile, led by value and quality.
ZBIO (Zenas BioPharma, Inc.): the counter-case, on fundamentals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
VSTMVSTM on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ZBIOZBIO on combined revenue and EPS growth.
Value
VSTMVSTM on the peer-relative Value factor, by 20 points.
Momentum
VSTMVSTM on the Momentum factor, by 11 points.
Lower downside
ZBIOZBIO carries the lower 1-month annualized volatility.
Analyst upside
VSTMVSTM on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | VSTM | ZBIO | Note |
|---|---|---|---|
| Implied upside to target | +126.2% | +96.4% | VSTM has more room |
| Target dispersion | +48.6% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 10 | 8 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor VSTM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | VSTM | 60 vs 47 |
| Fundamentals | ZBIOon balance | revenue growth -40.1% vs 9%; EPS growth -111.4% vs 6.8%; TTM ROE -7.4% vs -51.3%; gross margin 86.1% vs -6.6%; operating margin -193.7% vs -47.9% — ZBIO takes 3 of 5 decided legs, not all of them |
| Valuation | VSTM | Value 53 vs 33 |
| Technicals | VSTM | Price vs 50-day -3.6% vs -2%; vs 200-day 29.9% vs 10.5% |
| Risk Resilience | Even | Risk Resilience 36 vs 39 |
| Analyst expectations | VSTM | Target upside 126.2% vs 96.4% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of VSTM and ZBIO and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 13 points. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on VSTM.
How the comparison changed
120 daily snapshots · May 27 – Nov 13VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions.
- Today
- VSTM +13
- 60 vs 47
- 7 sessions ago
- VSTM +14
- 60 vs 46
- 30 sessions ago
- VSTM +14
- 57 vs 43
- 90 sessions ago
- VSTM +6
- 51 vs 45
The lead changed hands 2 times in this window, most recently on Aug 13 when VSTM moved ahead of ZBIO.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish / 1 neutral, conflicted
Only VSTM
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
3 bullish / 2 bearish / 1 neutral, conflicted
Only ZBIO
- Beta Spike Warning — bearish, risk_regime, long horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.61x)
- RSI Midline Reclaim — bullish, momentum, short horizon
Both carry 3 more signals that do not separate them: Golden Cross Active, ATR Expansion - Breakout Mode, EMA Ribbon Expansion Bullish.
VSTM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -3.08%, AIQ 0 points).
Price and the AIQ Score both moved up over the latest session (price +1.34%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1ZBIO closes the Value gap — currently 20 points behind, the largest single contributor to VSTM's edge.
- 2ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ZBIO leads on balance| Metric | VSTM | ZBIO |
|---|---|---|
| Revenue growth (YoY) | -40.1% | 9% |
| EPS growth (YoY) | -111.4% | 6.8% |
| Gross margin | 86.1% | -6.6% |
| Operating margin | -193.7% | -47.9% |
| Return on equity (TTM) | -7.4% | -51.3% |
| Debt to equity | 12.09 | 1.42 |
Performance
VSTM leads 4 of 6 windows| Metric | VSTM | ZBIO |
|---|---|---|
| 1 week (5 sessions) | -2.7% | -0.9% |
| 1 month (20 sessions) | -5.4% | 12.8% |
| 3 months (63 sessions) | 13.9% | -8.2% |
| 6 months (126 sessions) | 89.4% | 52.7% |
| Year to date | 6% | -22.9% |
| 1 year (252 sessions) | -3.9% | -21.8% |
Technicals
VSTM has the stronger structure| Metric | VSTM | ZBIO |
|---|---|---|
| RSI (14) | 41.6 | 50.1 |
| ADX (14) | 28.3 | 12.2 |
| Price vs 50-day | -3.6% | -2% |
| Price vs 200-day | 29.9% | 10.5% |
| Volatility (1M, annualized) | 72.4% | 65.7% |
Risk
Split| Metric | VSTM | ZBIO |
|---|---|---|
| Beta | 0.89 | 0.75 |
| Sharpe ratio | 0.32 | 0.26 |
| Sortino ratio | 0.49 | 0.34 |
| Max drawdown | -67.6% | -64.8% |
| Current drawdown | -23.1% | -35.1% |
| Annualized volatility | 74.2% | 95.3% |
| Value at risk (95%) | -7.2% | -7.3% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, VSTM or ZBIO?
On the Algovestiq AIQ Score, VSTM is the stronger of the two as of Nov 15, 2026, scoring 60 against ZBIO's 47. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is VSTM or ZBIO the better buy right now?
VSTM carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor VSTM over ZBIO?
The composite weights Quality, Value, Momentum and Risk Resilience. VSTM leads Value by 20 points; VSTM leads Quality by 17 points; VSTM leads Momentum by 11 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, VSTM or ZBIO?
Analyst price targets imply +126.2% upside for VSTM and +96.4% for ZBIO, so the Street currently favors VSTM. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, VSTM or ZBIO?
VSTM is the better-valued of the two on the peer-relative Value factor. VSTM on the peer-relative Value factor, by 20 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, VSTM or ZBIO?
ZBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, VSTM or ZBIO?
VSTM on the Momentum factor, by 11 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, VSTM or ZBIO?
ZBIO is the more resilient of the two, so the other name carries the higher downside risk. ZBIO carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is VSTM more profitable than ZBIO?
The profitability evidence is mixed: gross margin 86.1% vs -6.6%; operating margin -193.7% vs -47.9%; ttm roe -7.4% vs -51.3%. VSTM leads on two measures and ZBIO on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is VSTM's lead over ZBIO getting stronger or weaker?
VSTM lead: Stable — the AIQ differential has held near 13 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands 2 times in that window, most recently on 2026-08-13, when VSTM moved ahead of ZBIO.
What would change the VSTM vs ZBIO verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ZBIO closes the Value gap — currently 20 points behind, the largest single contributor to VSTM's edge; ZBIO's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; VSTM's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about VSTM and ZBIO?
VSTM: 2 bullish / 1 bearish / 1 neutral, conflicted. ZBIO: 3 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on VSTM is Golden Cross Active (bullish, long horizon). On ZBIO it is Golden Cross Active (bullish, long horizon).
Compare VSTM and ZBIO with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.